OpenAI 收购 Orchestra Bio 加速药物研发
towards acceleration of drug development, an extremely exciting and promising emerging application of our models
AI 导读
OpenAI 宣布收购帮助生物制药团队协调药物研发流程的平台 Orchestra Bio，并计划基于其生命科学研究模型与工具 Rosalind 优化相关运营。Greg Brockman 评论称，加速药物研发是 OpenAI 模型一个极其令人兴奋且前景广阔的新兴应用方向。
查看原帖We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner. Welcome @ashokaraj_ and team! https://t.co/vi51OhznQn
正文
当前显示原文，中文全文译文尚未就绪。
towards acceleration of drug development, an extremely exciting and promising emerging application of our models